New Law Challenges ‘Evils’ Of Pharma Profits, California Governor Claims
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
The independent source for health policy research, polling, and news.
1,081 - 1,100 of 3,361 Results
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
Eight teaching centers in California aim to train and retain doctors in medically underserved areas such as California鈥檚 Central Valley. They are among 57 such institutions across the country that may soon receive a boost in funding from Congress.
Complaints are rising against for-profit insurance companies that manage Medicaid for about 600,000 Iowans. The privatization of Medicaid is a national trend affecting more than half of the 74 million Americans who get their health care through the state-federal program.
"If it gets signed by this governor, it's going to send shock waves throughout the country,鈥 one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
Hospitals view adding trauma care as a potential profit tool, but experts say having more centers does not necessarily improve the system鈥檚 ability to respond to a mass casualty event.
Doctors offering this care charge a monthly fee for services that can be handled in the office. But patient advocates warn it is not insurance and offers no coverage for hospital or specialist care.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
The inspector general at Health and Human Services says defective pacemakers or defibrillators had to be replaced from 2005 through 2014, costing Medicare $1.5 billion.
Tom Price resigned from running the Department of Health and Human Services after a series of news stories detailing how he tallied more than $400,000 in private plane travel paid for by taxpayers.听
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
Medicaid covers about two-thirds of nursing home residents, but it pays less than other types of insurance.
At a political rally in March, President Donald Trump said drug prices are 鈥渙utrageous鈥 and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
The clinics, which serve many poor people, are tightening spending in case Congress doesn鈥檛 approve new funding for them before the government鈥檚 2018 fiscal year starts Sunday.
The insurer says hospital-based imaging services are too expensive and the independent facilities provide high-quality care.
The statement from the Maine senator came after the Congressional Budget Office said the bill would cause millions of people to become uninsured.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Sept. 30 marks the end of Medicare鈥檚 temporary offer to waive penalties for certain late Medicare enrollees with Affordable Care Act insurance coverage.
Agency says a removable cap will lower the risk of antibiotic resistant infections but some experts see it as a modest step in curbing the sort of deadly outbreaks that occurred a few years ago.
The company鈥檚 drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
听
漏 2026 麻豆女优